Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Cancer Clinical Trial

Official title:

A Phase I, Open-label, Multicenter, Dose Escalation and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05347628
• Other study ID #: PLB1004-I-01
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: August 25, 2020
• Est. completion date: November 30, 2024

Study information

• Verified date: July 2023
• Source: Avistone Biotechnology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of PLB1004, and to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs) and recommended phase II dose (RP2D).

Description:

The study includes a Dose-escalation Part and a Dose Expansion Part. The aim of the Dose-escalation Part is to estimate the MTD (if possible), identify the DLT (if possible) and the RP2D for PLB1004. The Dose Expansion Part is to further assess the clinical efficacy and safety of PLB1004.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 91
• Est. completion date: November 30, 2024
• Est. primary completion date: April 4, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Ability to understand and the willingness to sign a written informed consent document;

2. Aged at least 18 years old;

3. Histologically or cytologically confirmed advanced non-small cell lung cancer;

4. Patients with EGFR or HER2 mutations;

5. ECOG Performance Status of 0-2;

6. Life expectancy is not less than 12 weeks;

7. At least one measurable lesion as defined by RECIST1.1;

Exclusion Criteria:

1. For the Dose Expansion Part: Patients who have received prior treatment with Poziotinib or TAK788 or other EGFR/HER2 exon20 insertion inhibitors should be excluded;

2. Any cytotoxic drugs or other anticancer drugs from a previous treatment regimen within 14 days prior to the first dose of PLB1004;

3. Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting PLB1004 or who have not recovered from side effects of such procedure;

4. Thoracic radiotherapy to lung fields = 4 weeks prior to starting PLB1004. For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy = 2 weeks prior to starting PLB1004 or patients who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions = 2 weeks prior to starting PLB1004 is allowed;

5. Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with

PLB1004 and for the duration of the study:

• Strong inhibitors of CYP3A4
• Strong inducers of CYP3A4
• Inducers or inhibitors of P-gp

6. Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms;

7. Clinically significant, uncontrolled heart diseases;

8. Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, indolent malignancies that currently do not require treatment, and completely resectedcarcinoma in situ of any type;

9. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease;

10. History of hypersensitivity to active or inactive excipients of PLB1004 or drugs with a similar chemical structure or class to PLB1004;

11. Pregnant or nursing women;

12. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small-Cell Lung Cancer

Intervention

Drug:
• PLB1004
PLB1004 is a capsule in the form of 10mg and 40mg.

Locations

Country	Name	City	State
China	Guangdong General Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Avistone Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events (TEAEs)	A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.	2 years
Primary	DLTs of Orally Administered PLB1004	Toxicity will be evaluated according to the NCI CTCAE, Version 5.00. DLT will be defined as any of the events specified in the protocol that are considered by the investigator to be at least possibly related to therapy with study medications.	28 days
Primary	Maximum Tolerated Dose (MTD) of Orally Administered PLB1004	The MTD is the highest dose level at which the participant tolerates treatment without dose-limiting toxicities.	28 days
Primary	Recommended Phase II Dose (RP2D) of Orally Administered PLB1004	The RP2D is the maximum tolerated dose (MTD) or less. An RP2D less than the MTD may be chosen if aspects of tolerability or efficacy not encompassed by the MTD determination suggest utilizing a lower dose.	2 years
Secondary	Area Under the Curve (AUC) of PLB1004	The AUC values are based on the plasma concentration-time profile of PLB1004. To characterize the pharmacokinetics of PLB1004.	Up to approximately 28 days; Pre-dose and multiple time points post-dose
Secondary	Maximum plasma concentration (Cmax) of PLB1004	The Cmax values are based on the plasma concentration-time profile of PLB1004. To characterize the pharmacokinetics of PLB1004.	Up to approximately 28 days; Pre-dose and multiple time points post-dose
Secondary	Time to maximum plasma concentration (Tmax) of PLB1004	The Tmax values are based on the plasma concentration-time profile of PLB1004. To characterize the pharmacokinetics of PLB1004.	Up to approximately 28 days; Pre-dose and multiple time points post-dose
Secondary	Overall Response Rate (ORR)	ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.	3 years
Secondary	Progression-Free Survival (PFS)	PFS is defined as the time interval from the date of starting treatment until the first date at which the criteria for progressive disease (PD) according to RECIST 1.1 are met or death, whichever occurs first.	3 years
Secondary	Overall Survival (OS)	OS is defined as the time from date of starting treatment to date of death due to any cause.	3 years
Secondary	Disease Control Rate (DCR)	DCR is defined as the percentage of participants who have achieved CR, PR, or SD after the initiation of study drug.	3 years
Secondary	Duration of Response (DOR)	DOR is defined as the time from first documented response of CR or PR to date of first documented progression or death according to RECIST 1.1.	3 years